Your session is about to expire
← Back to Search
Usual Care Followed by I-SITE Intervention for Diabetic Retinopathy
N/A
Waitlist Available
Led By Yao Liu, MD, MS
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (data is retrospective to evaluate pre-intervention beginning november 2022) and 12, 24, and 36 months
Awards & highlights
Study Summary
This trial is testing a program called I-SITE to see if it can help maintain higher rates of diabetic eye screening using teleophthalmology in city health systems with multiple payers.
Who is the study for?
This trial is for individuals with type 1 or type 2 diabetes who are part of an urban health system and have had diabetic eye screenings. Participants' medical records must include specific ICD-10 codes for diabetes and billing data for teleophthalmology services.Check my eligibility
What is being tested?
The study tests the I-SITE program's effectiveness in maintaining high rates of diabetic eye screening through teleophthalmology, compared to usual care, within urban health systems that cater to multiple insurance payers.See study design
What are the potential side effects?
Since this trial focuses on implementing a service delivery method rather than a drug, traditional side effects are not applicable. However, there may be indirect consequences related to accessibility, satisfaction or accuracy of the teleophthalmology service.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ data collected monthly (retrospectively beginning november 2022 and up to 36 months prospectively)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~data collected monthly (retrospectively beginning november 2022 and up to 36 months prospectively)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Diabetic Screening Rate
Secondary outcome measures
Follow Up Rate For In-Person Eye Care Among Screen Positives
Monthly Teleophthalmology Use
Trial Design
1Treatment groups
Experimental Treatment
Group I: Usual Care Followed by I-SITE InterventionExperimental Treatment2 Interventions
Find a Location
Who is running the clinical trial?
University of Wisconsin, MadisonLead Sponsor
1,191 Previous Clinical Trials
3,167,696 Total Patients Enrolled
5 Trials studying Diabetic Retinopathy
7,772 Patients Enrolled for Diabetic Retinopathy
National Eye Institute (NEI)NIH
547 Previous Clinical Trials
1,400,157 Total Patients Enrolled
50 Trials studying Diabetic Retinopathy
40,945 Patients Enrolled for Diabetic Retinopathy
Yao Liu, MD, MSPrincipal InvestigatorUW School of Medicine and Public Health
2 Previous Clinical Trials
1,536 Total Patients Enrolled
2 Trials studying Diabetic Retinopathy
1,536 Patients Enrolled for Diabetic Retinopathy
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are individuals currently able to apply and participate in this ongoing research study?
"As per the details available on clinicaltrials.gov, recruitment for this study is not ongoing. The trial was initially listed on 3/19/2024 and last modified on 4/2/2024. However, despite this particular trial no longer accepting participants, there are currently 64 other trials actively enrolling subjects at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger